OrbiMed Capital GP IV LLC
CIK 1502240 · last filed 2024-07-02
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
RLYP price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
NEW YORK, NY 10022
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TELA | 10%+ Owner | 5,485,084 | $0.98 | $5.38M | $5.96M | 2 | 2024-07-02 |
| ALEC | 10%+ Owner | 1,921,804 | $1.83 | $3.52M | -$244.48M | 7 | 2020-04-16 |
| Principia Biopharma Inc. (PRNB) Delisted | 10%+ Owner | 1,605,713 | — | — | -$52.00M | 2 | 2019-05-22 |
| BOLD | 10%+ Owner | 4,129,638 | $2.41 | $9.95M | -$56.95M | 1 | 2017-09-29 |
| Relypsa Inc (RLYP) Delisted | 10%+ Owner | 7,664,171 | — | — | -$233.05M | 6 | 2015-12-23 |
| OTONOMY, INC. (OTIC) Delisted | Director | 2,245,300 | $0.08 | $172.9K | -$11.88M | 1 | 2015-11-19 |
| INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | Director | 1,120,609 | $19.00 | $21.29M | -$84.48M | 5 | 2015-07-21 |
| Mirati Therapeutics, Inc. (MRTX) Delisted | 10%+ Owner | 1,267,000 | $58.70 | $74.37M | $6.00M | 1 | 2015-02-05 |
| Anthera Pharmaceuticals Inc (ANTH) Delisted | Director | 116,594 | — | — | -$7.23M | 5 | 2013-02-01 |
Recent Filings · Page 3 of 3
30 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2014-08-19 | Relypsa Inc (RLYP) Delisted | Sell (S) | −2,970,000 | -$78.26M | EDGAR |
| 2013-11-20 | Relypsa Inc (RLYP) Delisted | Mixed | +29,824,653 | $23.49M | EDGAR |
| 2013-05-13 | INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | Exer (M) | +972 | $0 | EDGAR |
| 2013-04-15 | INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | Exer (M) | +1,947 | $0 | EDGAR |
| 2013-02-01 | Anthera Pharmaceuticals Inc (ANTH) Delisted | Buy (P) | +17,100,000 | $11.29M | EDGAR |
| 2012-10-16 | INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | Mixed | +6,451,902 | $15.00M | EDGAR |
| 2012-07-03 | Anthera Pharmaceuticals Inc (ANTH) Delisted | Sell (S) | −3,849,900 | -$2.83M | EDGAR |
| 2012-03-22 | Anthera Pharmaceuticals Inc (ANTH) Delisted | Sell (S) | −4,645,500 | -$11.51M | EDGAR |
| 2011-06-06 | Anthera Pharmaceuticals Inc (ANTH) Delisted | Sell (S) | −544,002 | -$4.43M | EDGAR |
| 2010-10-04 | Anthera Pharmaceuticals Inc (ANTH) Delisted | Buy (P) | +59,700 | $243.6K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.